New drug HRS-3095 aims to soothe stubborn hives
NCT ID NCT07613866
First seen Jun 25, 2026 · Last updated Jun 25, 2026
Summary
This Phase 2 trial tests whether the experimental drug HRS-3095 can reduce itching and wheals in adults with chronic spontaneous urticaria (hives) that isn't well controlled by antihistamines. About 190 participants will receive either the drug or a placebo daily for 4 weeks. The main goal is to see if the drug improves hive activity scores compared to placebo.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC SPONTANEOUS URTICARIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Affiliated Hangzhou First People's Hospital, School of Medicine, Westlake University
Hangzhou, Zhejiang, 310006, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Huashan Hospital Affiliated to Fudan University
Shanghai, Shanghai Municipality, 200040, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
HRS-3095 tablet
What this could lead to
If it works, this could point toward a new daily pill to better control chronic hives for people who don't get enough relief from antihistamines.
What could go wrong
This is an early Phase 2 trial with only 190 participants, so results may not apply to everyone. The drug may not prove more effective than placebo, and side effects are still being studied.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.